OOIR: Observatory of International Research

Papers

(The H4-Index of Journal of Hepatology is 100. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)

Article	Citations
A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement	2063
BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update	1472
Baveno VII – Renewing consensus in portal hypertension	874
EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update	671
COVID-19: Abnormal liver function tests	645
EASL recommendations on treatment of hepatitis C: Final update of the series☆	627
Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma	553
SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19	440
Global burden of primary liver cancer in 2020 and predictions to 2040	405
Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study	401
COVID-19 and the liver	350
Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study	348
The global prevalence of hepatitis D virus infection: Systematic review and meta-analysis	309
COVID-19: Discovery, diagnostics and drug development	285
Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials	283
The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology	282
Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients	276
Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort☆	273
Single-cell transcriptomic architecture and intercellular crosstalk of human intrahepatic cholangiocarcinoma	263
Hepatocyte pyroptosis and release of inflammasome particles induce stellate cell activation and liver fibrosis	261
A multisociety Delphi consensus statement on new fatty liver disease nomenclature	256
High rates of 30-day mortality in patients with cirrhosis and COVID-19	256
Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma	248
NAFLD as a driver of chronic kidney disease	246
Epidemiological pattern, incidence, and outcomes of COVID-19 in liver transplant patients	246

Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials	234
Update on NAFLD genetics: From new variants to the clinic	228
Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States	226
Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF	220
Molecular targeted therapies: Ready for “prime time” in biliary tract cancer	219
Hepatic encephalopathy: Novel insights into classification, pathophysiology and therapy	214
Systemic treatment of hepatocellular carcinoma: An EASL position paper	211
High mortality rates for SARS-CoV-2 infection in patients with pre-existing chronic liver disease and cirrhosis: Preliminary results from an international registry	199
The systemic inflammation hypothesis: Towards a new paradigm of acute decompensation and multiorgan failure in cirrhosis	198
Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores	186
Impact of COVID-19 on global HCV elimination efforts	179
Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: A systematic review and meta-analysis	167
Effect of sarcopenia on survival in patients with cirrhosis: A meta-analysis	166
EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients	165
Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma	164
A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis	161
Global burden of liver disease: 2023 update	158
Regulatory T-cell and neutrophil extracellular trap interaction contributes to carcinogenesis in non-alcoholic steatohepatitis	157
Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: Causality or casualty?	157
Epidemiology and risk-stratification of NAFLD-associated HCC	154
aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis	154
Hepatic stellate cell autophagy inhibits extracellular vesicle release to attenuate liver fibrosis	153
Single-cell genomics and spatial transcriptomics: Discovery of novel cell states and cellular interactions in liver physiology and disease biology	152
Sarcopenia and frailty in decompensated cirrhosis	147
Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages☆	147
Pathophysiology of decompensated cirrhosis: Portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction	146
Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis	146
Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy	146
The COVID-19 pandemic will have a long-lasting impact on the quality of cirrhosis care	144
Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study	139
HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: A meta-analysis	138
PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis	138
Animal models for liver disease – A practical approach for translational research	138
Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease – novel insights into cellular communication circuits	137
Single-cell atlas of tumor cell evolution in response to therapy in hepatocellular carcinoma and intrahepatic cholangiocarcinoma	130
Causal relationships between NAFLD, T2D and obesity have implications for disease subphenotyping	129
Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort	126
Prognosis of patients with hepatocellular carcinoma treated with immunotherapy – development and validation of the CRAFITY score	126
EASL Clinical Practice Guidelines on the management of hepatic encephalopathy	123
Analysis of antibody responses after COVID-19 vaccination in liver transplant recipients and those with chronic liver diseases	123
Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry	121
CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis	120
Heterogeneous immunogenomic features and distinct escape mechanisms in multifocal hepatocellular carcinoma	116
Acetyl-CoA carboxylase inhibition disrupts metabolic reprogramming during hepatic stellate cell activation	115
A new perspective on NAFLD: Focusing on lipid droplets	115
NAFLD-driven HCC: Safety and efficacy of current and emerging treatment options	115
Reply to: correspondence regarding “A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement”	114
Lytic cell death in metabolic liver disease	112
EASL Clinical Practice Guidelines on prevention and management of bleeding and thrombosis in patients with cirrhosis	111
Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma	111

Proton beam radiotherapy vs. radiofrequency ablation for recurrent hepatocellular carcinoma: A randomized phase III trial	110
A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis	110
Stereotactic body radiation therapy vs. radiofrequency ablation in Asian patients with hepatocellular carcinoma	109
Innate immune cells in cirrhosis	109
IL-17 signaling in steatotic hepatocytes and macrophages promotes hepatocellular carcinoma in alcohol-related liver disease	108
The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?	108
Repeated FIB-4 measurements can help identify individuals at risk of severe liver disease	108
Refining the Baveno VI elastography criteria for the definition of compensated advanced chronic liver disease	108
The microbiota in cirrhosis and its role in hepatic decompensation	107
Occult hepatitis B infection and hepatocellular carcinoma: Epidemiology, virology, hepatocarcinogenesis and clinical significance	107
Interleukin-22 ameliorates acute-on-chronic liver failure by reprogramming impaired regeneration pathways in mice	106
Exposure to environmental contaminants is associated with altered hepatic lipid metabolism in non-alcoholic fatty liver disease	106
Microbiota changes and intestinal microbiota transplantation in liver diseases and cirrhosis	106
Peptide SMIM30 promotes HCC development by inducing SRC/YES1 membrane anchoring and MAPK pathway activation	106
Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis	105
Circular RNA ACTN4 promotes intrahepatic cholangiocarcinoma progression by recruiting YBX1 to initiate FZD7 transcription	105
Rebleeding and mortality risk are increased by ACLF but reduced by pre-emptive TIPS	104
Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension	103
Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension	102
Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy	100
Younger patients with MAFLD are at increased risk of severe COVID-19 illness: A multicenter preliminary analysis	100
Association of liver abnormalities with in-hospital mortality in patients with COVID-19	100
MicroRNA-342-3p is a potent tumour suppressor in hepatocellular carcinoma	100
Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease	100
Extracellular vesicles as biomarkers in liver diseases: A clinician's point of view	100